Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
What 5 Analyst Ratings Have To Say About Cytokinetics
05:11pm, Friday, 10'th Jun 2022 Benzinga
Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
4
1
0
0
0
Last 30
Cytokinetics Announces Additional Results From REDWOOD-HCM to Be Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions
08:00pm, Friday, 03'rd Jun 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from a new analysis from REDWOOD-HCM (Randomized Eval
Cytokinetics to Participate in Upcoming Investor Conferences
04:00pm, Thursday, 02'nd Jun 2022
SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to par
Where Cytokinetics Stands With Analysts
01:01pm, Tuesday, 24'th May 2022 Benzinga
Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
4
0
0
0
0
Last 30
Cytokinetics Announces Data From REDWOOD-HCM OLE and GALACTIC-HF Presented as Late Breaking Science Presentations at the European Society of Cardiology Heart Failure 2022 Congress
03:30pm, Monday, 23'rd May 2022 GlobeNewswire Inc.
Data from Up to Six Months of Treatment with Aficamten Show Significant and Sustained Reductions in LVOT Gradients with Improvements in Functional Class, Symptoms, and Biomarkers
Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil
11:30am, Tuesday, 17'th May 2022 GlobeNewswire Inc.
FDA Plans to Convene Advisory Committee Meeting FDA Plans to Convene Advisory Committee Meeting
10 Biggest Price Target Changes For Monday
11:53am, Monday, 16'th May 2022 Benzinga
Needham cut the price target on Carvana Co. (NYSE: CVNA) from $121 to $80. Carvana shares rose 11.3% to $42.71 in pre-market trading.
Susquehanna cut Taboola.com Ltd. (NASDAQ: TBLA) price target f
Mizuho: these two biotech stocks are worth buying right now
04:35pm, Monday, 09'th May 2022
Biotech is one of the hardest hit sectors this year, with the SPDR S&P Biotech ETF now down 45% year-to-date. Still, a Mizuho analyst says the following two stocks are worth buying.
Cytokinetics, Incorporated (CYTK) CEO Robert Blum on Q1 2022 Results - Earnings Call Transcript
10:15pm, Wednesday, 04'th May 2022
Cytokinetics, Incorporated (NASDAQ:CYTK ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Diane Weiser - SVP of Corporate Communications and IR Robert Blum - President and
Cytokinetics (CYTK) Reports Q1 Loss, Misses Revenue Estimates
09:15pm, Wednesday, 04'th May 2022 Zacks Investment Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -9.68% and 77.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) Reports Q1 Loss, Misses Revenue Estimates
06:48pm, Wednesday, 04'th May 2022
Cytokinetics (CYTK) delivered earnings and revenue surprises of -9.68% and 77.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Cytokinetics (CYTK): Can Its 11.5% Jump Turn into More Strength?
08:11am, Monday, 02'nd May 2022 Zacks Investment Research
Cytokinetics (CYTK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down th
Strength Seen in Cytokinetics (CYTK): Can Its 11.5% Jump Turn into More Strength?
05:16am, Monday, 02'nd May 2022
Cytokinetics (CYTK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down th
Cytokinetics to Announce First Quarter Results on May 4, 2022
04:00pm, Wednesday, 20'th Apr 2022
SOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 4, 2022 at 4:00 PM
Cytokinetics: A Brighter Future In Muscle Biology
03:59pm, Monday, 11'th Apr 2022
Cytokinetics had a down year in 2019. They have since bounced back to deliver record-high revenues in 2021.
